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Epigenome-Wide Scan Identifies a Treatment-Responsive
Pattern of Altered DNA Methylation Among
Cytoskeletal Remodeling Genes in Monocytes and
CD4 T Cells From Patients With Behc¸et’s Disease
Travis Hughes,1 Filiz Ture-Ozdemir,2 Fatma Alibaz-Oner,2 Patrick Coit,1
Haner Direskeneli,2 and Amr H. Sawalha1
Objective. The pathogenesis of Behc¸et’s disease
(BD), an inflammatory disease with multisystem in-
volvement, remains poorly understood. This study was
undertaken to investigate whether there areDNAmethyl-
ation abnormalities in BD that might contribute to the
pathogenesis of the disease.
Methods. We examined genome-wide DNAmethyl-
ation patterns in monocytes and CD4 T cells from 16
male patients with untreated BD and age, sex, and
ethnicity–matched healthy controls. Additional samples
were collected from 12 of the same BD patients after
treatment and achievement of disease remission.
Genome-wide DNA methylation patterns were assessed
using the Infinium HumanMethylation450 BeadChip
array, which includes >485,000 individual methylation
sites across the genome.
Results. We identified 383 CpG sites in mono-
cytes, and 125 in CD4 T cells, that were differentially
methylated between BD patients and controls. Bioinfor-
matic analysis revealed a pattern of aberrant DNA
methylation among genes that regulate cytoskeletal
dynamics, suggesting that aberrant DNA methylation of
multiple classes of structural and regulatory proteins of
the cytoskeleton might contribute to the pathogenesis of
BD. Further, treatment of BD modified the differences
in DNA methylation observed in patients compared to
controls; indeed, among CpG sites that were differen-
tially methylated after disease remission versus before
treatment, there was widespread reversal of the direc-
tion of aberrant DNA methylation observed between the
patient and control groups.
Conclusion. The results of this epigenome-wide
study—the first such study in BD—provide strong evi-
dence that epigenetic modification of cytoskeletal dy-
namics underlies the pathogenesis of BD and its re-
sponse to treatment.
Behc¸et’s disease (BD) is an inflammatory disease
characterized by the presence of recurrent oral and
genital ulcers, skin lesions, and uveitis. Mucocutaneous
lesions in BD typically exhibit leukocyte infiltration,
primarily by T cells and monocytes (1). Widespread
enhancement of leukocyte motility and tissue infiltration
occurs in BD. Monocytes from patients with BD display
increased activity and promote increased neutrophil
adhesion (2). Further, levels of macrophage inflamma-
tory protein 1, which promotes lymphocyte chemotaxis,
are elevated in BD (3). Activated CD4 T cells play a
critical role in BD pathogenesis, and an expansion of
Th17 cells via interleukin-21 signaling and increased
levels of / T cells are observed (4–6).
Endothelial cell injury is common in BD. Levels
of soluble E-selectin molecules have been reported to be
increased in the serum of patients with active disease (7).
Vascular endothelial cell function becomes impaired in
response to oxidative damage (8). Disruption of tight
junctions between endothelial cells is mediated by
changes in class II myosin phosphorylation and remod-
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eling of the F-actin cytoskeleton (9). Cytoskeletal re-
modeling in endothelial and immune cells accompanies
lymphocyte adhesion and tissue infiltration in the nor-
mal inflammatory response (10). Treatments that dis-
rupt microtubule processing might be effective in limit-
ing the frequency and severity of mucocutaneous
symptoms in BD, but their exact mechanism of action
remains uncertain.
BD has a strong genetic component, as evidenced
by the geographic concentration of the disease along
the Old Silk Road (11). The most robust genetic asso-
ciation observed in BD to date is within the HLA region.
Recent evidence suggests that there are multiple inde-
pendent genetic susceptibility loci for BD in the HLA
class I region, with the strongest effect localized to
the genetic region between HLA-B and MICA (12).
Multiple associations outside of the HLA region have
also been reported in BD, including associations with
IL10, IL23R, UBAC2, STAT4, CCR1, KLRC4, ERAP1,
and GIMAP2/GIMAP4 (13). While there is a strong
genetic component to BD, genetic variation alone is not
sufficient to explain the heritability and pathogenesis of
the disease.
To date there have been no reported studies of
the involvement of DNA methylation (the addition of a
methyl group to the fifth carbon in cytosine rings within
CpG dinucleotides) in BD. However, there is a growing
body of evidence that changes in DNA methylation have
an important role in multiple immune-mediated diseases
(14–17). DNA methylation ex utero is primarily medi-
ated by DNA methyltransferase 1 and is generally a
repressive epigenetic mark. Hypermethylation of DNA
results in transcriptional gene repression, while hypo-
methylation is associated with a chromatin configuration
that is transcriptionally permissive (18).
Herein we report the results of an epigenome-
wide study of the methylation status of 485,000 indi-
vidual methylation sites across the genome, among
treatment-naive BD patients and healthy matched con-
trols. We also evaluated epigenome-wide DNA methyl-
ation status in individual BD patients before and after
treatment with achievement of disease remission. We
obtained evidence of widespread DNA methylation
changes in BD across the genome. Our data suggest that
DNA methylation changes in genes involved in cytoskel-
etal dynamics contribute to the pathogenesis of BD and
that restoration of DNA methylation of microtubule-
processing genes occurs following achievement of dis-
ease remission.
PATIENTS AND METHODS
Patient selection and sample collection. Sixteen male
BD patients and 16 healthy controls matched for age (5
years), sex, and ethnicity were recruited to participate in this
study. All patients were recruited from the rheumatology
clinics at Marmara University School of Medicine. Disease
manifestations of the patients are reported in Supplementary
Table 1 (on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.38409/abstract). All
patients studied had either not received treatment for BD or
had not received treatment for at least 3 months prior to
enrollment, and samples were collected at the initial study visit.
Samples were further collected from 12 of the 16 BD patients
following treatment and achievement of disease remission
(defined as the absence of any disease-associated symptoms or
organ involvement for at least 1 month). The study was
approved by the ethics committees and institutional review
boards at Marmara University School of Medicine and the
University of Michigan. All study participants provided written
informed consent prior to enrollment.
Isolation of monocytes and CD4 T cells and DNA
extraction. Peripheral blood mononuclear cells (PBMCs) were
isolated, by density-gradient centrifugation (Amersham Biosci-
ences), from fresh blood samples obtained from BD patients
and healthy controls. Monocytes and CD4 T cells were
purified from PBMCs by magnetic bead separation (Miltenyi
Biotec). The purity of isolated cell populations, confirmed by
flow cytometry using fluorochrome-conjugated antibodies
against CD14 (for monocytes) and CD4 (for T helper lympho-
cytes), was 90% for both monocytes and CD4 T cells.
Genomic DNA was obtained from isolated monocytes and
CD4 T cells using a DNeasy Blood and Tissue Kit (Qiagen).
Genome-wide DNA methylation profiling. Bisulfite
conversion was performed using an EZ DNA Methylation Kit
(Zymo Research). Whole-genome amplification of bisulfite-
converted DNA was performed prior to array hybridization.
An Infinium HumanMethylation450 BeadChip array kit was
used to assess the methylation status of 485,000 individual
methylation sites throughout the genome. This array covers
99% of RefSeq genes, with an average of 17 CpG sites per
gene across the promoter region, 5-untranslated region (5-
UTR), first exon, gene body, and 3-UTR. It also covers 96%
of CpG islands. Non-CpG methylated sites recently identified
in human stem cells are also covered, as are microRNA
promoter regions.
Quality control, identification of differentially methyl-
ated CpG sites, and bioinformatic analysis. Comparisons of
DNA methylation levels between BD patients and healthy
controls were performed separately for monocytes and CD4
T cells. Differences in DNA methylation associated with
treatment for BD were also assessed separately in monocytes
and CD4 T cells. Differential methylation analysis was
performed using the Genome Studio methylation package.
Beta values were used to represent the percent methylation at
each CpG site, and were calculated using the ratio of intensi-
ties between methylated and unmethylated alleles, as follows:
  methylated/(unmethylated  methylated  100).
Methylation data were normalized in Genome Studio.
Prior to analysis a total of 50,446 probes were removed due to
the presence of single-nucleotide polymorphisms within 10
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bases of the CpG target sequence. No probes were observed to
have detection P values greater than 0.05. The P value for
differential methylation between patients and controls was
calculated using the following equation:
P  z 
patientcontrol
s2control
Ncontrol

s2patient
Npatient

where s is the standard deviation estimate and z is the 2-sided
tail probability of the standard normal distribution. The stan-
dard deviation estimate s is a function of  and was calculated
as s  A2  B  C, where A  0.1511, B  0.1444, and
C  0.01646. A, B, and C values were derived by Illumina by
repeatedly measuring loci with known methylation fractions
ranging from 0 to 1 and fitting a parabola to the standard
deviation as a function of . A differential methylation score
(DiffScore) for each probe was calculated as follows:
DiffScore  10  sgnpatient  control   log10P)
where sgn(i)  1 when i  0, sgn(i)  0 when i  0, and
sgn(i)  1 when i 	 0.
Probes with an average methylation difference (
) of
at least 10% (BD patients versus controls) or 5% (patients
before treatment versus patients after treatment) and differ-
ential methylation scores of at least 22 (equivalent to a
differential methylation P value of0.01), after adjustment for
multiple testing using a Benjamini and Hochberg false discov-
ery rate (FDR) of 5%, were considered differentially methyl-
ated. A linear regression model was fitted to estimate batch
effect in differentially methylated loci using R, and no batch
effect was detected in our study.
We performed bioinformatic analysis to identify ca-
nonical pathways and cellular processes that were enriched
among differentially methylated CpG sites, through Gene
Ontology (GO) analysis using DAVID software (19). We
Figure 1. Differential methylation of CpG sites in monocytes and CD4 T cells from patients with Behc¸et’s disease (BD). A, Differential methylation
in 16 male BD patients compared to 16 age, sex, and ethnicity–matched healthy controls. In monocytes, 383 CpG sites were differentially methylated, of
which 254 were hypomethylated and 129 were hypermethylated. In CD4 T cells, 125 CpG sites were differentially methylated, of which 67 were
hypomethylated and 58 were hypermethylated. Within each panel, hypomethylated CpG sites are represented on the left and hypermethylated sites on the
right. For each CpG site the average beta values, which represent the percent methylation, are shown (in red for BD patients; in black for controls).
B, Differential methylation of a number of genes related to cytoskeletal dynamics in monocytes and CD4 T cells from BD patients compared to controls.
Values are the mean  SEM fraction of methylation.   P 	 0.01 versus controls.
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examined enrichment among OMIM diseases, Kyoto Encyclo-
pedia of Genes and Genomes pathways, PANTHER pathways,
molecular function (MF), cellular component (CC), and bio-
logic process (BP) gene ontology terms among differentially
methylated gene sets. A background of all RefSeq genes was
selected for GO analysis in DAVID. Network interaction
analysis was performed using GeneMania (20).
RESULTS
Behc¸et’s disease–associated differences in DNA
methylation. We observed significant differences be-
tween BD patients and healthy controls in DNA methyl-
ation across the genome (Figure 1A). In monocytes, 383
CpG sites in 228 genes were differentially methylated
between patients and controls, with 129 hypermethy-
lated CpG sites and 254 hypomethylated sites (Table 1
and Supplementary Table 2 [on the Arthritis & Rheuma-
tology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.38409/abstract]). In CD4 T cells, there
were 125 differentially methylated CpG sites (67 hypo-
methylated and 58 hypermethylated) in 62 genes (Table
2 and Supplementary Table 3). While hypomethylation
was more prevalent in monocytes, we observed a high
degree of concordance between CD4 T cells and
monocytes in terms of differential methylation; indeed,
59 of the 125 CpG sites that were differentially methyl-
ated in CD4 T cells from BD patients compared to
controls were also differentially methylated in mono-
cytes from BD patients.
Bioinformatic findings. Bioinformatic assess-
ment revealed an enrichment of genes and pathways
associated with cytoskeletal remodeling among genes
that were differentially methylated in monocytes from
BD patients versus healthy controls, and GO term
analysis using DAVID software revealed significant en-
Table 1. CpG sites that were differentially methylated in monocytes from Behc¸et’s disease patients compared to monocytes from healthy controls*
Probe Gene symbol Gene name
Methylation (),
patients
Methylation (),
controls 
 P
Hypomethylated sites
cg07211972 CBS Cystathionine--synthase 0.374 0.604 0.230 1.59  1034
cg15971518 PRG2 Proteoglycan 2, bone marrow 0.282 0.470 0.187 6.85  1025
cg17509989 RGS14 Regulator of G protein signaling 14 0.242 0.421 0.179 5.35  1024
cg16006841 RGS14 Regulator of G protein signaling 14 0.341 0.519 0.178 4.67  1021
cg06060754 RGS14 Regulator of G protein signaling 14 0.315 0.488 0.173 3.74  1020
cg05248234 FSCN2 Fascin homolog 2, actin-bundling
protein, retinal
0.280 0.450 0.170 2.97  1020
cg06559318 HLA-DRB6 Major histocompatibility complex,
class II, DR6
0.282 0.444 0.162 2.85  1018
cg05398700 WDR20 Tryptophan–aspartic acid repeat
domain 20
0.644 0.805 0.161 5.38  1025
cg23646109 BCYRN1;
GJB1
Brain cytoplasmic RNA 1; gap
junction protein, 1, 32 kd
0.751 0.907 0.156 1.59  1034
cg17220055 HIVEP3 Human immunodeficiency virus
type I enhancer binding protein 3
0.401 0.554 0.153 7.7  1015
Hypermethylated sites
cg08684580 BAIAP2L1 Brain-specific angiogenesis inhibitor
1–associated protein 2–like 1
0.434 0.234 0.200 8.89  1035
cg24634471 JRK Jerky homolog (mouse) 0.630 0.434 0.195 8.89 1035
cg10596483 JRK Jerky homolog (mouse) 0.522 0.349 0.172 8.89 1035
cg26053840 GLO1 Glyoxalase I 0.465 0.305 0.160 8.89 1035
cg17965159 LRMP Lymphoid-restricted membrane
protein
0.594 0.434 0.160 8.89  1035
cg03329597 MYH15 Myosin heavy chain 15 0.442 0.284 0.159 8.89  1035
cg07921503 CHST12 Carbohydrate (chondroitin 4)
sulfotransferase 12
0.226 0.072 0.155 8.89  1035
cg10105218 CD53 CD53 molecule 0.397 0.249 0.149 8.89  1035
cg06915202 BAIAP2L1 Brain-specific angiogenesis inhibitor
1–associated protein 2–like 1
0.469 0.321 0.148 8.89  1035
cg14040931 GNE Glucosamine (UDP-N-acetyl)-2-
epimerase/N-acetylmannosamine
kinase
0.488 0.342 0.146 8.89  1035
* The sites listed are those that were the most highly hypo- or hypermethylated in patients compared to controls.
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richment of genes related to cytoskeletal dynamics and
function among these 228 genes (Table 3). Specifically,
genes in the cytoskeletal protein binding, actin cytoskel-
eton, and M band categories (MF 0008092, CC 0015629,
and CC 0031430, respectively) showed the most signifi-
cant enrichment among genes that were differentially
methylated in monocytes.
Among the 62 genes that were differentially
methylated in CD4 T cells, the most prominent ac-
cording to GO term analysis were related to antigen
processing and presentation, with this finding driven
primarily by differential methylation in 3 loci within the
HLA class II region (Table 4). Enrichment of genes
associated with cytoskeletal processes was also observed
in CD4 T cells, but to a lesser degree than in mono-
cytes. In CD4 T cells, actin cytoskeleton (CC 0015629),
cytoskeletal regulation by Rho GTPase (PANTHER
P00016), and cytoskeletal protein binding (MF 0008092)
were all significantly enriched (FDR 	 0.20).
Differential methylation of genes associated with
cytoskeletal remodeling. The set of differentially meth-
ylated CpG sites in monocytes and CD4 T cells from
patients with BD compared to healthy controls included
CpG sites in genes that are involved in multiple levels of
cytoskeletal regulation, structure, and function (Supple-
mentary Tables 4 and 5 and Supplementary Figures 1
and 2 [http://onlinelibrary.wiley.com/doi/10.1002/
art.38409/abstract]). Differential methylation of Rho
GTPase genes, which play a central role in regulating
actin cytoskeletal remodeling (21), was observed in
CD4 T cells. RAC1 (probe cg18404925) exhibited the
highest degree of hypomethylation (  0.106 [patients]
Table 2. CpG sites that were differentially methylated in CD4 T cells from Behc¸et’s disease patients compared to CD4 T cells from healthy
controls*
Probe Gene symbol Gene name
Methylation (),
patients
Methylation (),
controls 
 P
Hypomethylated sites
cg18404925 RAC1 Cell migration–inducing gene 5
protein
0.106 0.308 0.202 1.79  1034
cg17509989 RGS14 Regulator of G protein signaling 14 0.343 0.545 0.201 1.42  1027
cg00103771 HLA-DRB6 Major histocompatibility complex,
class II, DR6
0.453 0.644 0.192 3.28  1025
cg06559318 HLA-DRB6 Major histocompatibility complex,
class II, DR6
0.265 0.448 0.183 2.85  1024
cg16006841 RGS14 Regulator of G-protein signaling 14 0.507 0.678 0.171 1.02  1020
cg27362989 HLA-DRB5 Major histocompatibility complex,
class II, DR5
0.322 0.489 0.167 1.05  1018
cg23646109 BCYRN1,
GJB1
Brain cytoplasmic RNA 1; gap
junction protein, 1, 32 kd
0.737 0.897 0.160 1.79  1034
cg01778345 GDAP2 Ganglioside-induced
differentiation–associated
protein 2
0.485 0.630 0.145 1.6  1013
cg19516921 HLA-DRB5 Major histocompatibility complex,
class II, DR5
0.326 0.470 0.144 2.08  1013
cg06060754 RGS14 Regulator of G protein signaling 14 0.475 0.612 0.137 6.29  1012
Hypermethylated sites
cg16474696 MRI1 Methylthioribose-1-phosphate
isomerase 1; mediator of RhoA-
dependent invasion
0.430 0.244 0.186 1.02  1034
cg08684580 BAIAP2L1 Brain-specific angiogenesis inhibitor
1–associated protein 2–like 1
0.444 0.268 0.176 1.02  1034
cg24634471 JRK Jerky homolog (mouse) 0.564 0.390 0.174 1.02  1034
cg07796016 LCE1C Late cornified envelope 1C 0.755 0.596 0.158 1.02  1034
cg04798314 SMYD3 SET and MYND domain–
containing 3
0.705 0.550 0.155 1.02  1034
cg16913477 C3orf39 Chromosome 2 open-reading frame 0.898 0.758 0.141 1.02  1034
cg00501169 NBPF4 Neuroblastoma breakpoint family,
member 4
0.811 0.672 0.139 1.02  1034
cg10596483 JRK Jerky homolog (mouse) 0.485 0.346 0.139 3.39  1012
cg26679884 TUBB8 Tubulin, 8 class VIII 0.455 0.317 0.138 1.75  1012
cg25755428 MRI1 Methylthioribose-1-phosphate
isomerase 1; mediator of RhoA-
dependent invasion
0.238 0.100 0.138 1.02  1034
* The sites listed are those that were the most highly hypo- or hypermethylated in patients compared to controls.
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and 0.308 [controls]) in CD4 T cells from patients with
BD. RAC1 regulates T lymphocyte adhesion via integrin
and controls actin cytoskeletal dynamics (22,23). Hyper-
methylation of the gene that encodes RhoJ was also
observed in CD4 T cells from BD patients. Further,
ARHGAP24, a Rho GTP–associated protein, was hyper-
methylated in BD patient monocytes.
Differential methylation of genes involved in
actin processing, including FSCN2, BAIAP2L1,
FILIP1L, and SSH1, was demonstrated in monocytes
from patients with BD. Hypermethylation of BAIAP2L1
and hypomethylation of FSCN2 were observed in mono-
cytes and CD4 T cells from these patients (Figure 1B
and Supplementary Tables 4 and 5). ANK1, coding for
ankyrin 1, is associated with attachment of integral
membrane proteins to the actin cytoskeleton and was
also hypermethylated in monocytes from BD patients
compared to healthy controls.
Altered methylation of nonmuscle myosin genes
was detected in both monocytes and CD4 T cells from
BD patients compared to controls. We observed hyper-
methylation of myosin heavy chain 15 (MYH15) in
Table 3. Gene ontology analysis of CpG sites that were differentially methylated in monocytes from Behc¸et’s disease patients compared to
monocytes from healthy controls*
Category Description Genes P FDR, %
MF: 0008092 Cytoskeletal protein binding OBSCN, MYH15, SSH1, MYO1C, FSCN2, BAIAP2L1,
BAIAP2, MYO1D, RPH3AL, SYNPO2, HOMER2,
TNNI2, MPRIP, KIF1B, ANK1
0.0024 3.37
CC: 0015629 Actin cytoskeleton MYH15, FSCN2, MYO1C, MYO1D, FERMT1,
SYNPO2, SLC9A3R1, BMF, FILIP1L, TNNI2
0.0037 4.75
CC: 0031430 M band OBSCN, ANK1, ENO1 0.0044 5.59
CC: 0016459 Myosin complex MYH15, MYO1C, MYO1D, BMF, FILIP1L 0.0064 8.04
CC: 0030016 Myofibril HDAC4, OBSCN, ANK1, MYH15, TNNI2, ENO1 0.0088 10.87
MF: 0008093 Cytoskeletal adaptor activity ANK1, BAIAP2L1, BAIAP2 0.0097 12.92
CC: 0005737 Cytoplasm TGOLN2, MYH15, CHMP6, C16ORF70, MIPEP,
CUL3, NLRC4, ANK1, EDARADD, BSG,
BCL2L14, BAIAP2, HAL, PDE4D, RPTOR, NPC1,
ATP2C1, TRIM34, PCMTD1, FILIP1L, ANKFY1,
MCTS1, TRIM39, SH3GL1, SSH1, PFKFB3, GNE,
CLU, CALR, AZI1, SCRIB, ADAP1, JRK, ARG1,
LPCAT1, GALNS, DHODH, RNF11, DYRK4,
GLO1, TRAF6, BMF, TEC, B4GALT5, PTPN7,
OBSCN, UAP1, ABR, MYO1C, NXF2, RPS9,
SULT6B1, HOMER2, MPRIP, TNNI2, HDAC4,
LASS3, HIVEP3, COPS2, MAD1L1, FERMT1,
IL4I1, CD93, CHST12, TRIM6, CHST15, ACAD8,
GOLGA3, PIGY, RPH3AL, ARHGAP24, PRKCB,
EML4, EIF4G1, KIF1B, HIPK3, LRMP, GNAS,
PCYOX1, TRIM6-TRIM34, SEC14L1, STK40,
DAPP1, CCS, ETV6, PCSK6, EXOC2, ENO1,
FAM125B, NXF2B, SYNPO2, PARK2, STAB2,
CSGALNACT1, MRPL21, RPS6KA2, TRPC4AP,
CYP4F3, RAB38, SLC15A4, VPS28, ACSM5, CBS
0.011 13.81
CC: 0043292 Contractile fiber HDAC4, OBSCN, ANK1, MYH15, TNNI2, ENO1 0.012 15.07
CC: 0005856 Cytoskeleton MAD1L1, MYH15, SSH1, GNE, DNAH3, FERMT1,
AZI1, ANK1, BMF, DLG2, FSCN2, MYO1C,
MYO1D, NXF2B, NXF2, SYNPO2, PDE4D,
SLC9A3R1, ARHGAP24, HOMER2, RGS14,
TNNI2, MPRIP, EML4, KIF1B, TBCD, FILIP1L
0.014 16.44
CC: 0031672 A band OBSCN, ANK1, ENO1 0.014 16.72
BP: 0009225 Nucleotide-sugar metabolic
process
CSGALNACT1, UAP1, GNE 0.012 18.04
CC: 0005802 Trans-Golgi network k TGOLN2, ATP2C1, C16ORF70, GNAS 0.015 18.32
MF: 0003779 Actin binding MYH15, SSH1, FSCN2, MYO1C, BAIAP2L1, MYO1D,
SYNPO2, HOMER2, TNNI2, MPRIP
0.015 18.75
CC: 0012505 Endomembrane system MAD1L1, BSG, BCL2L14, PIGY, MYO1C, CHMP6,
C16ORF70, RPH3AL, CSGALNACT1, NPC1,
KIF1B, ATP2C1, CHST12, LRMP, GNAS, CYP4F3,
GOLGA3
0.017 19.91
* FDR  false discovery rate; MF  molecular function; CC  cellular component; BP  biologic process.
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monocytes and CD4 T cells. In monocytes, we further
observed hypomethylation of myosin 1C, (MYO1C) and
hypermethylation of MYO1D and MPRIP (Supplemen-
tary Table 4).
Differential methylation of genes encoding
microtubule-related proteins was also found in both cell
types. Hypomethylation of TBCD, KIF1B, and DNAH3
was detected in monocytes, and TUBB8 was hyperm-
ethylated in BD patient CD4 T cells compared to
controls (Figure 1B and Supplementary Tables 4 and 5).
In both monocytes and CD4 T cells there was signifi-
cant hypomethylation of multiple CpG sites in RGS14, a
gene that encodes a microtubule-associated protein (24)
(Figure 1B and Supplementary Tables 4 and 5).
Alteration of DNA methylation in microtubule
processing genes after treatment for Behc¸et’s disease.
We found widespread differences in DNA methylation
between monocytes and CD4 T cells from untreated
BD patients with active disease and samples obtained
from the same patients following treatment and achieve-
ment of disease remission. A lower threshold for DNA
methylation differences (
 	 0.05) was applied to
enable detection of smaller changes in DNA methylation
and partial restoration (by at least 50%) of the DNA
methylation changes observed in patients with BD. We
detected a total of 1,426 differentially methylated CpG
sites in monocytes after treatment; of these, 636 were
hypomethylated and 790 were hypermethylated. In
CD4 T cells, a total of 2,044 CpG sites were differen-
tially methylated following treatment, with 1,012 hypo-
methylated and 1,032 hypermethylated.
Bioinformatic analysis of genes that displayed
differential methylation in BD patients following treat-
ment revealed enrichment of genes in multiple GO
categories, including some that are related to microtu-
bules, in both cell types (Supplementary Table 6 [on the
Arthritis & Rheumatology web site at http://online
library.wiley.com/doi/10.1002/art.38409/abstract]). In
monocytes, microtubule cytoskeleton (CC 0015630), mi-
crotubule organizing center (CC 0005815), cytoskeleton
Table 4. Gene ontology analysis of CpG sites that were differentially methylated in CD4 T cells from Behc¸et’s disease patients compared to
CD4 T cells from healthy controls*
Category Description Genes P FDR, %
KEGG: hsa05310 Asthma HLA-DQB1, EPX, PRG2, HLA-DRB5, HLA-
DQA1
8.21  107 7.42  104
KEGG: hsa05416 Viral myocarditis HLA-DQB1, MYH15, RAC1, HLA-DRB5,
HLA-DQA1
3.14  105 0.0284
KEGG: hsa04612 Antigen processing and
presentation
HLA-DQB1, HLA-DRB5, NFYA, HLA-DQA1 0.0013 1.21
CC: 0042613 Class II MHC protein complex HLA-DQB1, HLA-DRB5, HLA-DQA1 0.0029 3.32
KEGG: hsa05330 Allograft rejection HLA-DQB1, HLA-DRB5, HLA-DQA1 0.0042 3.74
KEGG: hsa05332 Graft-versus-host disease HLA-DQB1, HLA-DRB5, HLA-DQA1 0.0049 4.36
KEGG: hsa04940 Type 1 diabetes mellitus HLA-DQB1, HLA-DRB5, HLA-DQA1 0.0057 5.03
BP: 0002504 Antigen processing and
presentation of peptide or
polysaccharide antigen via
class II MHC
HLA-DQB1, HLA-DRB5, HLA-DQA1 0.0043 6.06
KEGG: hsa04672 Intestinal immune network for
IgA production
HLA-DQB1, HLA-DRB5, HLA-DQA1 0.0077 6.74
CC: 0015629 Actin cytoskeleton MYH15, FSCN2, MYOM2, FERMT1, TNNI2 0.0064 7.18
KEGG: hsa05320 Autoimmune thyroid disease HLA-DQB1, HLA-DRB5, HLA-DQA1 0.0083 7.26
OMIM Celiac disease, susceptibility to HLA-DQB1, HLA-DQA1 0.011 8.60
CC: 0043234 Protein complex HLA-DQB1, MYH15, TOLLIP, FERMT1,
NFYA, HLA-DQA1, GJB1, TNNI2,
MYOM2, HLA-DRB5, TUBB8, IFFO1,
NCOR2, GOLGA3, GABRP
0.008 8.90
PANTHER: P00016 Cytoskeletal regulation by Rho
GTPase
RHOJ, MYH15, RAC1, TUBB8 0.012 9.00
CC: 0042611 MHC protein complex HLA-DQB1, HLA-DRB5, HLA-DQA1 0.011 11.90
CC: 0032991 Macromolecular complex HLA-DQB1, MYH15, TOLLIP, FERMT1,
NFYA, HLA-DQA1, GJB1, TNNI2, JRK,
MYOM2, HLA-DRB5, TUBB8, IFFO1,
GOLGA3, NCOR2, GABRP
0.019 19.77
MF: 0008092 Cytoskeletal protein binding MYH15, FSCN2, BAIAP2L1, FRMD4A,
RPH3AL, TNNI2
0.018 19.79
* KEGG  Kyoto Encyclopedia of Genes and Genomes; MHC  major histocompatibility complex (see Table 3 for other definitions).
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organization (BP 0007010), and cytoskeleton (CC
0005856) genes were enriched. Microtubule cytoskele-
ton was also among the top 20 terms obtained in GO
term analysis of CD4 T cells after treatment.
Altered methylation of genes associated with
microtubule structure and organization was found in
both monocytes and CD4 T cells following treatment
(Supplementary Tables 7 and 8). Hypomethylation of
tubulin genes TUBA3C and TUBA3D and tubulin po-
lymerizing promoting protein (TPPP) was observed after
treatment of BD and achievement of disease remission.
Further, we observed significant alteration of the methyl-
ation of kinesin and dynein genes in both monocytes and
CD4 T cells. KIF2A was hypermethylated in both cell
types following treatment.
Treatment-induced reversal of DNA methylation
changes in monocytes and CD4 T cells from Behc¸et’s
disease patients. Alterations in DNA methylation pat-
terns occurring in BD patients after achievement of
disease remission were found to counteract DNAmethyl-
ation differences between BD patients and healthy
controls that had been observed pretreatment. Among
CpG sites that were differentially methylated after treat-
ment versus before, there was almost exclusive reversal
of the direction of aberrant methylation demonstrated
between patients and controls (Figure 2A). In a com-
Figure 2. Reversal of changes in DNA methylation in Behc¸et’s disease (BD) patients following treatment. A, CpG sites that were differentially
methylated in individual BD patients after versus before treatment (differential score	 22, 
 	 0.05), plotted according to the differences in DNA
methylation observed between BD patients and healthy controls (x-axes) and the change in methylation upon treatment (y-axes). In each panel, CpG
sites that were hypomethylated in BD patients are represented on the left of the vertical dashed line, and hypermethylated sites on the right. CpG
sites with increased and decreased methylation following treatment are represented above and below the horizontal dashed line, respectively.
CpG sites in the upper left and lower right quadrants are those in which treatment acted to reverse differences between BD patients and controls.
Enrichment of treatment-responsive CpG sites in the upper left and lower right quadrants of the plots demonstrates that treatment-induced reversal
of BD methylation differences occurred frequently. B, Methylation changes in differentially methylated CpG sites in BD patient monocytes that also
displayed differential methylation in individual patients after disease remission was achieved. There were a total of 94 such sites, and in 93 of these
(represented in the figure), the direction of methylation change in individual patients after versus before remission was opposite to the direction of
change observed between patients and controls. Red bars represent the difference in percent methylation between patients and controls; blue bars
represent the difference in percent methylation on the same CpG sites in patients after achievement of disease remission compared to the same
patients before treatment.
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parison of methylation differences identified between
BD patients and healthy controls and those detected
within individual BD patients before and after treat-
ment, there were 94 overlapping CpG sites among 69
genes in monocytes and 9 overlapping CpG sites among
7 genes in CD4 T cells. In both cell types, treatment
reversed BD-associated differences in DNA methyl-
ation. In 93 of the 94 CpG sites that displayed differ-
ences in BD monocytes following treatment, the direc-
tion of methylation change was opposite to that
observed between BD patients and controls (Figure 2B).
In many cases DNA methylation in BD patients was
completely restored following treatment, to levels simi-
lar to those in controls (Supplementary Table 9 [http://
onlinelibrary.wiley.com/doi/10.1002/art.38409/abstract]).
DISCUSSION
In this first reported epigenomic study of BD, we
have obtained evidence of widespread and reversible
patterns of altered DNA methylation in this disease. Of
particular interest, epigenetic dysregulation in BD was
evident across multiple levels of cytoskeletal organiza-
tion including actin binding, Rho GTPase enzymes,
motor proteins, and microtubule structure. Cytoskeletal
rearrangement is a process involved in locomotion, focal
adhesion, and cellular proliferation in leukocytes. Our
data suggest that aberrant epigenetic regulation of cyto-
skeletal remodeling genes in BD might underlie the
increased leukocyte migration and tissue infiltration
central to pathogenesis of the disease.
Among the differentially methylated genes de-
tected in BD, we demonstrated hypomethylation of
cytoskeletal genes implicated in increased chemotaxis in
normal lymphocytes and invadopodia formation in can-
cer. Fascin plays a central role in filopodia formation
and potentiates invasive migration of cancer cells
(25,26), and we observed hypomethylation of fascin
actin-bundling protein 2 (FSCN2) in monocytes and
CD4 T cells from patients with BD. Hypomethylation
of SSH1, a cofilin-phosphatase that regulates actin
filament dynamics of cell migration (27), was found in
monocytes, but not CD4 T cells, from BD patients. In
monocytes and CD4 T cells, we demonstrated hyper-
methylation of BAIAP2L1 (IRTKS), which functions in
actin bundling and cell migration (28,29).
In CD4 T cells, RAC1 displayed the highest level
of hypomethylation in BD patients compared to controls.
Further, partial restoration of reduced RAC1 methylation
was observed in patients after achievement of disease
remission. Differential methylation of RAC1 accessory
proteins including the actin regulatory protein
ARHGAP24, which functions to reduce expression of Rac1
and Cdc42 in murine podocytes (30), was also detected in
monocytes from BD patients. MPRIP, which was hyper-
methylated in BD patient monocytes, is involved in the
formation of actin structures that are involved in T cell
migration through the activation of Rac1 (31). We ob-
served hypermethylation of synaptojanin 2 (SYNJ2), a
Rac1 effector that regulates clathrin-mediated endocytosis
and invadopodia formation (32), in BD patient monocytes
and CD4 T cells following treatment.
In lymphocytes, myosin motor proteins perform a
variety of cellular functions including regulation of the
cytoskeleton, projections of the cell surface, and cell
membrane processes (e.g., phagocytosis) (33). Myosin
light chain phosphorylation influences monocyte migra-
tion through the endothelial barrier (34). Class II myo-
sins play a role in cell motility through regulating actin
polymerization in the formation of lamellipodia. Non-
muscle myosin heavy chain IIA (MYH9) is involved in
abrogation of T cell motility upon antigen recognition
and focal adhesion (35). In BD monocytes, we observed
hypermethylation of obscurin (OBSCN) and ANK1. Ob-
scurin is involved in myofibril organization through its
regulation of TC10 (RhoQ) and also interacts with
ANK1 (36,37). MYH15 was hypermethylated in BD
monocytes and CD4 T cells. In addition, altered
methylation of myomesin 2 (MYOM2) was observed in
BD CD4 T cells.
Immune complex formation might be involved in
the pathogenesis of BD (38). Interestingly, cytoskeletal
components are frequent targets for autoantibody for-
mation in BD, and antibodies recognizing intermediate
filaments of the cytoskeleton have been observed (39).
Further, autoantibodies targeting cofilin 1, tubulin-like,
and actin-like self antigens have been demonstrated in a
subset of patients (40).
We examined the effect of treatment and disease
remission on DNA methylation changes in monocytes
and CD4 T cells from patients with BD. Colchicine is
commonly used as a first-line treatment for mucocuta-
neous manifestations of BD and was the primary med-
ication used to manage the disease in the patients
included in this study. The effectiveness of colchicine in
limiting the severity of BD is thought to be due to its
ability to attenuate leukocyte chemotaxis (41). Colchi-
cine is known to limit cell motility through the disruption
of microtubule organization and structure. Consistent
with this known effect, a number of genes related to
microtubule formation and organization were differen-
tially methylated in both monocytes and CD4 T cells
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from BD patients following colchicine treatment. Hyper-
methylation of the kinesin gene KIF2A and hypomethy-
lation of TPPP were observed in monocytes and CD4
T cells from treated patients. Interestingly, kinesin defi-
ciency results in weakened intercellular adhesion with-
out affecting adherens junction components at the
plasma membrane (42). Up-regulation of TPPP has been
reported to induce altered microtubule structure and
reduce cell viability (43).
In BD monocytes we observed hypomethylation
of tubulin folding cofactor D (TBCD), which was re-
versed upon treatment. Similarly, hypomethylation of
tripartite motif containing 39 (TRIM39) in BD mono-
cytes was reversed following treatment. A genetic asso-
ciation between TRIM39, which encodes a RING
domain–containing E3 ubiquitin ligase, and BD has
been previously reported in a Japanese population (44).
Of interest, we also detected hypomethylation of
UBAC2, which encodes a protein with a ubiquitin-
associated domain, in BD patient monocytes, suggesting
a role of this gene product in ubiquitination pathways.
UBAC2 is a confirmed genetic susceptibility locus in BD,
and the risk allele in this locus has been shown to be
associated with increased UBAC2 messenger RNA ex-
pression in PBMCs (45). The DNA hypomethylation
detected in UBAC2 was almost completely restored
upon disease remission in our patients. Differential
methylation in several HLA class II loci was notable
primarily in CD4 T cells from patients with BD.
Specifically, hypomethylation across several CpG sites in
HLA-DRB5 and HLA-DRB6 was observed. There is
currently no strong evidence supporting the presence of
a genetic susceptibility locus within HLA class II in BD,
despite the demonstration of multiple independent sus-
ceptibility loci located within HLA class I (12).
In summary, the current results provide evidence
of epigenetic remodeling and reversal of specific DNA
methylation changes following the achievement of re-
mission in an inflammatory disease. This emphasizes the
potential for epigenetic studies to reveal novel aspects of
disease pathogenesis, which might lead to the identifi-
cation of new targets for disease monitoring and treat-
ment. Our findings strongly support the notion that
dynamic and reversible epigenetic changes in cytoskel-
etal remodeling genes play an important role in the
pathogenesis of BD. We have demonstrated that follow-
ing treatment, BD-associated variations in DNA methyl-
ation undergo epigenetic remodeling, with reversal of
DNA methylation differences observed between BD
patients and controls. DNA methylation changes that
are restored upon disease remission represent potential
biomarkers for disease activity and treatment respon-
siveness in BD. A large longitudinal study will be
necessary to fully explore the utility of these altered
DNA methylation changes as biomarkers. Future inves-
tigations to characterize the capacity of specific DNA
methylation changes in BD and other inflammatory and
autoimmune diseases to predict disease manifestations,
clinical course, and response to treatment are warranted.
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